Cat.#: ASSD-123
Description | Competitive fluorescent β2-adrenoceptor antagonist. Displays selectivity for β2 over β1 and β3 (apparent KD values are 9.21, 7.76 and 7.09 respectively). Antagonizes the activity of isoprenaline, a non-selective β-adrenoceptor agonist. Exhibits no intrinsic agonist activity. |
Synonyms | β2-633-AN2 |
Size | 500 μg |
Applications | For imaging at β1 / β2 / β3 adrenoceptors use solutions up to 100 nM. |
Molecule Weight | 894 |
Purity | >95% |
Solubility | Soluble in DMSO |
Excitation | 633 nm |
Emission | 650 nm |
Storage | Store at -20° C |
Shipping | Shipped at 4°C |
Important | We strongly recommend storing this product away from light and briefly sonicating the sample when using to ensure it is fully dissolved and the solution is homogeneous. However, we do not recommend using the product after subjecting it to repetitive freeze-thaw cycles. |
Citation Guidance | If you use our product in a scientific publication, please cite it as "Ace Therapeutics Cat.#". Click here to submit your paper's PubMed ID (PMID) to receive rewards. |
Cat.# | Name | Size | Price |
---|---|---|---|
ASSD-139 | Adenosine A1AR Affinity-Based Probe (AfBP) (AC139) | 50 μg | inquiry |
ASSD-104 | Hoechst 33258 (AC104) | 25 mg, 100 mg | inquiry |
ASSD-191 | Fluorescein 6-Isothiocyanate, Isomer 2, 95% (AC191) | 100 mg | inquiry |
ASSD-203 | Bis(2,2′-bipyridine)-4,4′-dicarboxybipyridine-ruthenium di(N-succinimidyl ester) bis(hexafluorophosphate) (AC203) | 5 mg | inquiry |
ASSD-101 | Cresyl Violet Solution (1%) (AC101) | 250 mL, 500 mL, | inquiry |
ASSD-177 | Fluorescein 5-Maleimide (AC177) | 25 mg | inquiry |
ASSD-107 | Modified Mayer's Hematoxylin (AC107) | 125 mL, 250 mL, 2×250mL | inquiry |
ASSD-122 | Fluorescent β2 antagonist [(±)-propranolol] (AC122) | 500 μg | inquiry |
ASSD-204 | 7-Diethylamino-3-[N-(2-maleimidoethyl)carbamoyl]coumarin (AC204) | 1 mg, 5 mg | inquiry |
ASSD-198 | NHS-5(6)Carboxyrhodamine (AC198) | 25 mg | inquiry |
Ace Therapeutics is a global leading provider of stroke research services. We are committed to accelerating progress in stroke research and drug development.